$599

Foundayo UK Approval; Veru CY Q2 ’26 Earnings; Ascletis New Ph1 QM AOM Studies; Novo Partners with AWS; Neurocrine Ph1 Triple Agonist Study

A series of cardiometabolic-related news items has been observed from MHRA/Lilly, Veru, Ascletis Pharma, Novo Nordisk, and Neurocrine Biosciences. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Already a member? Log in here